Safety and Immunogenicity of COVID-19 BBIBP-CorV Vaccine in Children 3-12 Years Old.
Khaled GreishAbdulla AlawadhiAhmed JaradatAmer J AlmarabhehMarwa AlMadhiJaleela JawadBasma AlsaffarEjlal AlalawiAdel AlsayyadAfaf Merza MohamedBatool AlalawiDonia QayedAhmed HumaidanManaf Al-QahtaniPublished in: Vaccines (2022)
Two doses of COVID-19 BBIBP-CorV on the subjects aged between 3 to 12 has good safety and tolerance and can induce an effective immune response and neutralizing antibody titer.